📊 ZURA Key Takeaways
Is Zura Bio Ltd (ZURA) a Good Investment?
Zura Bio is a pre-revenue stage biopharmaceutical company with an exceptionally strong balance sheet ($109.4M cash, zero debt, 9.05x current ratio) providing 1.7+ years of operating runway. However, the absence of revenue, -$64.9M annual free cash flow, and -$75.2M operating losses create significant execution risk dependent entirely on clinical/regulatory success rather than financial fundamentals.
Why Buy Zura Bio Ltd Stock? ZURA Key Strengths
- Fortress balance sheet with $109.4M cash and zero long-term debt
- Excellent liquidity position (9.05x current ratio, quick ratio) with minimal operational liabilities
- Improving loss trajectory (net loss down 30.9% YoY, indicating operational efficiency gains)
- Minimal capital expenditure burden ($113K) preserving cash for core operations
ZURA Stock Risks: Zura Bio Ltd Investment Risks
- Pre-revenue stage with no visibility into commercial success or path to profitability
- Negative free cash flow of -$64.9M annually, consuming ~59% of available cash reserves annually
- Limited runway of approximately 1.7 years at current burn rate before capital constraints
- Binary outcome dependence on clinical trial success and regulatory approvals; execution risk is clinical, not financial
- Likely shareholder dilution ahead as additional fundraising may be required
Key Metrics to Watch
- Cash burn rate trajectory and quarterly operating cash flow trends
- Revenue recognition milestones and first commercial product launch timing
- Clinical trial phase advancement and regulatory approval status
- Cash runway sustainability and need for secondary capital raises
- Operating expense efficiency as company scales
Zura Bio Ltd (ZURA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.05x current ratio provides a solid financial cushion.
ZURA Profit Margin, ROE & Profitability Analysis
ZURA vs Healthcare Sector: How Zura Bio Ltd Compares
How Zura Bio Ltd compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zura Bio Ltd Stock Overvalued? ZURA Valuation Analysis 2026
Based on fundamental analysis, Zura Bio Ltd has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zura Bio Ltd Balance Sheet: ZURA Debt, Cash & Liquidity
ZURA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zura Bio Ltd's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.60 indicates the company is currently unprofitable.
ZURA Revenue Growth, EPS Growth & YoY Performance
Zura Bio Ltd Dividends, Buybacks & Capital Allocation
ZURA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zura Bio Ltd (CIK: 0001855644)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_060420.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_060418.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_060416.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_060414.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_060413.xml | View → |
❓ Frequently Asked Questions about ZURA
What is the AI rating for ZURA?
Zura Bio Ltd (ZURA) has an AI rating of HOLD with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZURA's key strengths?
Claude: Fortress balance sheet with $109.4M cash and zero long-term debt. Excellent liquidity position (9.05x current ratio, quick ratio) with minimal operational liabilities.
What are the risks of investing in ZURA?
Claude: Pre-revenue stage with no visibility into commercial success or path to profitability. Negative free cash flow of -$64.9M annually, consuming ~59% of available cash reserves annually.
What is ZURA's revenue and growth?
Zura Bio Ltd reported revenue of N/A.
Does ZURA pay dividends?
Zura Bio Ltd does not currently pay dividends.
Where can I find ZURA SEC filings?
Official SEC filings for Zura Bio Ltd (CIK: 0001855644) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZURA's EPS?
Zura Bio Ltd has a diluted EPS of $-1.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ZURA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Zura Bio Ltd has a HOLD rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ZURA stock overvalued or undervalued?
Valuation metrics for ZURA: ROE of -67.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ZURA stock in 2026?
Our dual AI analysis gives Zura Bio Ltd a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ZURA's free cash flow?
Zura Bio Ltd's operating cash flow is $-64.8M, with capital expenditures of $113.0K.
How does ZURA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -67.6% (avg: 15%), current ratio 9.05 (avg: 2).